Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma

The purpose of this study is to determine if giving an experimental drug called venetoclax in combination with lenalidomide and rituximab is safe and effective for treating people with Mantle Cell Lymphoma (MCL).

Trial Details

NCT ID
NCT03523975
Phase
PHASE1 / PHASE2
Sponsor
City of Hope Medical Center
Status
RECRUITING
Cancer Type
Non-Hodgkin Lymphoma Lymphoma
Interventions
  • Venetoclax
  • Lenalidomide
  • Rituximab
Locations (sample)
  • Duarte, California, United States|34.13945,-117.97729
  • Ann Arbor, Michigan, United States|42.27756,-83.74088
  • Columbus, Ohio, United States|39.96118,-82.99879
  • Charlottesville, Virginia, United States|38.02931,-78.47668

Key Eligibility Criteria

  • Age ≥18 years
  • Diagnosis of mantle cell lymphoma (MCL) established by histologic assessment
  • Laboratory, radiographic, physical exam findings and/or symptoms attributable to MCL
  • ECOG Performance Status (Eastern Cooperative Oncology Group Performance Status: an attempt to quantify cancer patients' general well-being and acti…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Hodgkin Lymphoma Lymphoma Trials on Trialify →